Your new post is loading...
The Lancet, Early Online Publication, 16 November 2012
doi:10.1016/S0140-6736(12)61854-6Cite or Link Using DOI
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial
Dr Arto A Palmu MD a , Jukka Jokinen PhD b, Dorota Borys MD c, Heta Nieminen MD a, Esa Ruokokoski MSc b, Lotta Siira MSc d, Taneli Puumalainen MD e f, Patricia Lommel MSc c, Marjan Hezareh PhD c, Marta Moreira MD c, Lode Schuerman MD c, Terhi M Kilpi MD b
The Finnish Invasive Pneumococcal disease (FinIP) vaccine trial was designed to assess the effectiveness of a pneumococcal vaccine containing ten serotype-specific polysaccharides conjugated to Haemophilus influenzae protein D, tetanus toxoid, and diphtheria toxoid as the carrier proteins (PHiD-CV10) against invasive pneumococcal disease.
